Product Description: Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that can selectively neutralize TGFβ1[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Lord DM, et, al. Structure-based engineering to restore high affinity binding of an isoform-selective anti-TGFβ1 antibody. MAbs. 2018 Apr;10(3):444-452.